TargED Biopharmaceuticals BV raises €39m in Series A financing

Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures  participated in the financing. Seed investors FIRST (Managed by BioGeneration Ventures), Curie Capital and Utrecht Health Seed Fund also joined the consortium. TargED Biopharmaceuticals BV said it will use the proceeds to accelerate development of its lead compound, Microlyse that enzymatically fights thromboses. TargED will focus development on two initial indications: acquired Thrombotic Thrombocytopenia Purpura (aTTP) and Acute Ischemic Stroke (AIS).

TargED’s lead product, Microlyse, is a first-in-class small antibody (“VhH”) that delivers trombolytic enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.  Microlyse is the first compound to achieve targeted enzyme delivery, using a single domain antibody (VhH), directly to blood clots. Due to the targeted nature of the therapy, it is expected to lead to a superior side effect profile alongside the potential for exceptional potency compared to current agents. Microlyse’s unique mechanism of action allows for potential applications in a variety of indications involving thrombosis, including the life-threatening disease aTTP.

Following the closing of the financing the Board of TargED will include: Thijs Cohen Tervaert, Inkef Capital (Chair), Olivier Litzka, Andera Partners, Mariette van der Velden-Roesink, Curie Capital, Jan Van den Bossche, Fund+, Roger Franklin, Hadean Ventures and Jacob Lange Moresco, Sunstone Life Science Ventures.